Single vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia

Abstract Bacillus anthracis, Yersinia pestis, and Francisella tularensis are the causative agents of Tier 1 Select Agents anthrax, plague, and tularemia, respectively. Currently, there are no licensed vaccines against plague and tularemia and the licensed anthrax vaccine is suboptimal. Here we repor...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Qingmei Jia, Richard Bowen, Barbara Jane Dillon, Saša Masleša-Galić, Brennan T. Chang, Austin C. Kaidi, Marcus A. Horwitz
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2018
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/039eb01266304f9db9d89d2a778bed41
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:039eb01266304f9db9d89d2a778bed41
record_format	dspace
spelling	oai:doaj.org-article:039eb01266304f9db9d89d2a778bed412021-12-02T11:40:17ZSingle vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia10.1038/s41598-018-24581-y2045-2322https://doaj.org/article/039eb01266304f9db9d89d2a778bed412018-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-018-24581-yhttps://doaj.org/toc/2045-2322Abstract Bacillus anthracis, Yersinia pestis, and Francisella tularensis are the causative agents of Tier 1 Select Agents anthrax, plague, and tularemia, respectively. Currently, there are no licensed vaccines against plague and tularemia and the licensed anthrax vaccine is suboptimal. Here we report F. tularensis LVS ΔcapB (Live Vaccine Strain with a deletion in capB)- and attenuated multi-deletional Listeria monocytogenes (Lm)-vectored vaccines against all three aforementioned pathogens. We show that LVS ΔcapB- and Lm-vectored vaccines express recombinant B. anthracis, Y. pestis, and F. tularensis immunoprotective antigens in broth and in macrophage-like cells and are non-toxic in mice. Homologous priming-boosting with the LVS ΔcapB-vectored vaccines induces potent antigen-specific humoral and T-cell-mediated immune responses and potent protective immunity against lethal respiratory challenge with all three pathogens. Protection against anthrax was far superior to that obtained with the licensed AVA vaccine and protection against tularemia was comparable to or greater than that obtained with the toxic and unlicensed LVS vaccine. Heterologous priming-boosting with LVS ΔcapB- and Lm-vectored B. anthracis and Y. pestis vaccines also induced potent protective immunity against lethal respiratory challenge with B. anthracis and Y. pestis. The single vaccine platform, especially the LVS ΔcapB-vectored vaccine platform, can be extended readily to other pathogens.Qingmei JiaRichard BowenBarbara Jane DillonSaša Masleša-GalićBrennan T. ChangAustin C. KaidiMarcus A. HorwitzNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 8, Iss 1, Pp 1-20 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Qingmei Jia Richard Bowen Barbara Jane Dillon Saša Masleša-Galić Brennan T. Chang Austin C. Kaidi Marcus A. Horwitz Single vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia
description	Abstract Bacillus anthracis, Yersinia pestis, and Francisella tularensis are the causative agents of Tier 1 Select Agents anthrax, plague, and tularemia, respectively. Currently, there are no licensed vaccines against plague and tularemia and the licensed anthrax vaccine is suboptimal. Here we report F. tularensis LVS ΔcapB (Live Vaccine Strain with a deletion in capB)- and attenuated multi-deletional Listeria monocytogenes (Lm)-vectored vaccines against all three aforementioned pathogens. We show that LVS ΔcapB- and Lm-vectored vaccines express recombinant B. anthracis, Y. pestis, and F. tularensis immunoprotective antigens in broth and in macrophage-like cells and are non-toxic in mice. Homologous priming-boosting with the LVS ΔcapB-vectored vaccines induces potent antigen-specific humoral and T-cell-mediated immune responses and potent protective immunity against lethal respiratory challenge with all three pathogens. Protection against anthrax was far superior to that obtained with the licensed AVA vaccine and protection against tularemia was comparable to or greater than that obtained with the toxic and unlicensed LVS vaccine. Heterologous priming-boosting with LVS ΔcapB- and Lm-vectored B. anthracis and Y. pestis vaccines also induced potent protective immunity against lethal respiratory challenge with B. anthracis and Y. pestis. The single vaccine platform, especially the LVS ΔcapB-vectored vaccine platform, can be extended readily to other pathogens.
format	article
author	Qingmei Jia Richard Bowen Barbara Jane Dillon Saša Masleša-Galić Brennan T. Chang Austin C. Kaidi Marcus A. Horwitz
author_facet	Qingmei Jia Richard Bowen Barbara Jane Dillon Saša Masleša-Galić Brennan T. Chang Austin C. Kaidi Marcus A. Horwitz
author_sort	Qingmei Jia
title	Single vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia
title_short	Single vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia
title_full	Single vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia
title_fullStr	Single vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia
title_full_unstemmed	Single vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia
title_sort	single vector platform vaccine protects against lethal respiratory challenge with tier 1 select agents of anthrax, plague, and tularemia
publisher	Nature Portfolio
publishDate	2018
url	https://doaj.org/article/039eb01266304f9db9d89d2a778bed41
work_keys_str_mv	AT qingmeijia singlevectorplatformvaccineprotectsagainstlethalrespiratorychallengewithtier1selectagentsofanthraxplagueandtularemia AT richardbowen singlevectorplatformvaccineprotectsagainstlethalrespiratorychallengewithtier1selectagentsofanthraxplagueandtularemia AT barbarajanedillon singlevectorplatformvaccineprotectsagainstlethalrespiratorychallengewithtier1selectagentsofanthraxplagueandtularemia AT sasamaslesagalic singlevectorplatformvaccineprotectsagainstlethalrespiratorychallengewithtier1selectagentsofanthraxplagueandtularemia AT brennantchang singlevectorplatformvaccineprotectsagainstlethalrespiratorychallengewithtier1selectagentsofanthraxplagueandtularemia AT austinckaidi singlevectorplatformvaccineprotectsagainstlethalrespiratorychallengewithtier1selectagentsofanthraxplagueandtularemia AT marcusahorwitz singlevectorplatformvaccineprotectsagainstlethalrespiratorychallengewithtier1selectagentsofanthraxplagueandtularemia
_version_	1718395621954551808

Single vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia

Ejemplares similares